Pfiz­er, Astel­las win pri­or­i­ty re­view for Xtan­di sN­DA; Hemi­spherx changes its name

→ The FDA has grant­ed Pfiz­er $PFE and Astel­las pri­or­i­ty re­view for a la­bel ex­pan­sion for Xtan­di, the prostate can­cer drug it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.